Showing results (61-70 of 130) with videos related to
Sort By:
Pageof 13
Hypertension (Dallas, Tex. : 1979)|August 1, 1991
Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibitionM Clozel, H Kuhn, F Hefti, et al.Journal of Molecular Medicine (Berlin, Germany)|June 3, 1999
Endothelin antagonism with bosentan: a review of potential applicationsS Roux, V Breu, S I Ertel, et al.Expert Opinion on Investigational Drugs|July 5, 2005
The pharmacology of bosentanV Breu, S I Ertel, S Roux, et al.Proceedings of the National Academy of Sciences of the United States of America|February 1, 1983
Pro-dynorphin peptides are found in the same neurons throughout rat brain: immunocytochemical studyS J Watson, H Khachaturian, L Taylor, et al.Circulation|September 1, 1993
Influence of the status of the renin-angiotensin system on the effect of cilazapril on neointima formation after vascular injury in ratsJ P Clozel, R K Müller, S Roux, et al.Current Medicinal Chemistry|April 8, 2003
Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agentsC Boss, S Richard-Bildstein, T Weller, et al.Neurosurgery|July 1, 1995
The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasmT Shigeno, M Clozel, S Sakai, et al.The American Journal of Physiology|February 1, 1995
Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic ratsS Eddahibi, B Raffestin, M Clozel, et al.Journal of Cardiovascular Pharmacology|December 1, 1994
Role of endothelin during reperfusion after ischemia in isolated perfused rat heartP H Dagassan, V Breu, M Clozel, et al.Journal of Cardiovascular Pharmacology|January 1, 1993
In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiologyM Clozel, V Breu, G A Gray, et al.Pageof 13